Clinical Trial

Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose

Study acronym: BERBEVIS-DFG-0
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Assessing the effects of a nutraceutical supplement (Berbevis™) in adults with impaired fasting glucose (100-126 mg/dL) and BMI between 25 and 35. Ninety participants will be assigned to three parallel groups receiving Berbevis™ at increasing daily doses (500 mg, 750 mg, and 1000 mg) for 2 months.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-24; most recent amendment 2025-11-23.
Trial Details
NCT Number NCT06955234
Lead Sponsor Azienda di Servizi alla Persona di Pavia
Conditions Impaired Fasting Glucose (IFG)
Enrollment 90 participants
Start Date 2026-06-15
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-25